Biotech / MedTech
Temasek’s ClavystBio, Lightstone Ventures back Allay Therapeutics’ $57.5M Series D financing
Allay Therapeutics, a clinical-stage biotechnology company, announced last Thursday the completion of a $57.5 million Series D financing round with leading global investors.
Hong Kong’s PHASE Scientific raises $34M Series A round to advance urine-based diagnostic technology for early disease detection
PHASE Scientific International Limited, a Hong Kong-based biotechnology company, announced Tuesday the successful completion of a $34 million Series A funding round.
Unlocking Southeast Asia’s multi-billion dollar biotech potential With AI
With partnerships across both government and private sectors, Southeast Asia can create an ecosystem that supports sustainable, long-term growth in AI-powered healthcare, enabling breakthroughs that improve patient outcomes and save lives.
Malaysia, Japan seal $310M in green bioeconomy
Malaysia and Japan have marked a new milestone in green bioeconomy cooperation with the signing of three strategic agreements worth MYR 1.34 billion ($310 million) at Expo 2025 Osaka.
Thailand’s MUU secures strategic investment from A2D Ventures, Leave a Nest Japan and a Japanese food conglomerate
MUU, Thailand’s first animal-free dairy biotech startup, has secured strategic investment from A2D Ventures, Leave a Nest Japan, and another leading Japanese food conglomerate.
Nourish Ingredients partners CABIO Biotech for global commercial scale of precision fermentation fats
In partnership with Chinese biotechnology company CABIO Biotech, Australian animal-free fats and precision fermentation startup Nourish Ingredients has successfully completed its first commercial production of Tastilux®, its potent meaty fat.
HKUST partners SIIC to launch Hong Kong biotechnology fund
The Hong Kong University of Science and Technology (HKUST) and Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC) have announced the establishment of the Hong Kong Biotechnology Fund (HKBF) to foster innovation in the life sciences sector.
Chitose Bio Evolution raises $49M through third-party allotment for expansion
Chitose Bio Evolution, a Singapore-based biotech firm and the headquarters of Chitose Group, has announced the issuance of new shares of JPY 7.3 billion ($49 million) through a third-party allotment for expansion.
Accelerating new drug development with AI in APAC
Clinical trials and the process of new drug development generate some of the highest-quality data in the world. The use of #AI in these represents a transformative shift that promises to make studies in drug development more efficient, accurate, and patient-centric.
Singapore’s Ignition AI Accelerator partners Pfizer to advance biopharma sector with AI
Ignition AI Accelerator, a collaborative initiative between NVIDIA, Tribe, and Digital Industry Singapore (DISG), has announced a a strategic partnership with global biopharmaceutical leader Pfizer to advance biopharma sector with artificial intelligence (AI).
